PwC advice to Pfizer to sell-off

In May 2010 Pfizer Inc.. (Pfizer), the world's largest research-based biomedical and pharmaceutical company, appointed PwC UK finance team as the company's principal financial advisor to the global divestiture program. This was followed by extensive evaluation of global manufacturing network following its acquisition of Wyeth Inc.. In October 2009. It is a wonderful achievement for PwC and demonstrate the ability of the company's North East finance team to manage a global command with regional focus on North East offer This command is supported by Pfizer iconic relationship and reputation with Pfizer PwC has developed over the past four years. PwC team, led by Paul Mankin, first worked with Pfizer in Morpeth factory sales in 2006. Since then, Pfizer has appointed Paul and his team led to six additional projects around the world including the United States, Ireland, Italy and Germany. During this PwC team has drawn on extensive expertise in the sector of a skilled team of pharmacists and PwC global network makes it possible to provide local expertise with international transactions Pfizer. PwC has started work under a new mandate with a total of seven divestitures in the United States and Europe. As part of this mandate Amit Bhalla, assistant director in corporate finance at Newcastle, starting a nine-month assignment in the United States in September last year. Amit, who worked on a number of releases of Pfizer, is currently based in New York and in addition to coordinating Pfizer divestment program worked hard to develop relationships with U.S. corporations. For the purpose Amit required to register as a broker-dealer under the U.S. federal safety regulations.